Patients (b) and (c) are usually treated with anti-angina and antiplatelet therapy and patient (a) may not be on any cardiac medications. The clinical presentation must be considered in the context of other factors, eg age, gender, hypertension,dyslipidemias,positive family history of premature coronary artery disease, diabetes, chronic kidney disease, cigarette smoking, and use of drugs such a...

Preview Hypertension, dyslipidemia, insulin resistance, and hyperinsulinemia--acknowledged risk factors for coronary artery disease--are all more common in persons with non-insulin-dependent diabetes than in nondiabetic persons. The interrelationships of these risk factors are becoming increasingly recognized. This article discusses the dyslipidemias commonly seen in type II diabetes and descri...

Background Obesity is a major public health issue in Brazil and in the world, increasing the rate of mortality due to comorbidities like: type-2 diabetes mellitus (DM2), arterial hypertension (AH), dyslipidemias, among others. Conventional obesity treatments show little effect in the long term, leading to an increase in the search for bariatric surgery as an alternative for the control and heal...

Statins used in the treatment of dyslipidemias are top-selling drugs in the world. Economical production of statins in industrial scale is challenging, because the side chain of statins is a 3,5-dihydroxyacid derivative consisting of two asymmetric centers. The most prominent methods for the preparation of the side chain are based on biocatalysis and surveyed in this review.

Oral fixed-dose niacin extended release/simvastatin is associated with clinically relevant improvements in plasma lipid profiles, including lowering of non-high-density lipoprotein cholesterol levels, relative to simvastatin monotherapy in patients with mixed dyslipidemias who had not responded fully to simvastatin monotherapy, and is generally well tolerated.

BACKGROUND Dyslipidemias are the major cause for atherosclerosis. They may act synergistically with nonlipid risk factors to increase atherogenesis. In the present study, we examined the effects of dyslipidemias from childhood to adulthood and their interaction with nonlipid risk factors on markers of subclinical atherosclerosis. METHODS AND RESULTS Study subjects were participants of the lon...

INTRODUCTION — There are a variety of different lipid disorders that can occur as either a primary event or secondary to some underlying disease [1]. (See "Secondary causes of dyslipidemia".) The primary dyslipidemias are associated with overproduction and/or impaired removal of lipoproteins (table 1). The latter defect can be induced by an abnormality in either the lipoprotein itself or in the...